President Halstead sells entire 41,583-share position in ITCI for $3.7M across 5 transactions at avg $88.79
Michael Halstead, President of Intra-Cellular Therapies, executed 5 separate sales totaling 41,583 shares for $3,692,100.03 on November 12–13, 2024, reducing his holdings to 0 shares post-transaction. This represents a complete liquidation of his equity stake, executed at a blended average price of $88.79, near the stock's 52-week high of $91.57. His prior sales at ITCI show mixed timing: only 1 of 5 were well-timed at the 90-day mark, indicating his historical sell decisions at this ticker have not consistently preceded declines. The company remains unprofitable with a net income of $-26,324,000.00 in the latest quarter, though annual revenue growth reached +85.5%, and the stock has appreciated +17.3% over the past 30 days and +17.1% over 90 days.